Analysts Issue Forecasts for LEXX FY2028 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at Zacks Research issued their FY2028 EPS estimates for shares of Lexaria Bioscience in a research note issued on Tuesday, February 10th. Zacks Research analyst J. Vandermosten forecasts that the company will post earnings of ($0.28) per share for the year. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share.

Lexaria Bioscience (NASDAQ:LEXX) last announced its quarterly earnings data on Tuesday, January 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.14 million. Lexaria Bioscience had a negative net margin of 1,685.84% and a negative return on equity of 226.58%.

A number of other research firms also recently commented on LEXX. Wall Street Zen downgraded Lexaria Bioscience from a “hold” rating to a “sell” rating in a report on Sunday, December 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lexaria Bioscience in a research note on Monday, December 29th. Finally, HC Wainwright cut their price objective on shares of Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating on the stock in a report on Friday, December 26th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Lexaria Bioscience has an average rating of “Hold” and a consensus target price of $1.50.

Lexaria Bioscience Price Performance

Lexaria Bioscience stock opened at $0.62 on Wednesday. The stock has a market cap of $15.44 million, a PE ratio of -1.11 and a beta of 0.56. The stock’s fifty day moving average is $0.76 and its two-hundred day moving average is $0.91. Lexaria Bioscience has a 1-year low of $0.46 and a 1-year high of $1.90.

Hedge Funds Weigh In On Lexaria Bioscience

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in Lexaria Bioscience by 25.7% in the fourth quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock valued at $136,000 after purchasing an additional 44,939 shares during the period. Byrne Asset Management LLC boosted its stake in shares of Lexaria Bioscience by 236.8% during the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock worth $65,000 after buying an additional 74,180 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Lexaria Bioscience during the third quarter worth about $28,000. 13.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.